Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Net Income Loss of $313.75 million for the year ending 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +212.8% in Net Income Loss from 2024 to 2025.
- This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Net Income Loss has grown by 1,295.3%.
- Historical annual values: Fiscal year 2025: $313.75 million | Fiscal year 2024: -$278.16 million | Fiscal year 2023: -$440.24 million | Fiscal year 2022: -$1.13 billion | Fiscal year 2021: -$852.82 million | Fiscal year 2020: -$858.28 million | Fiscal year 2019: -$886.12 million | Fiscal year 2018: -$761.50 million | Fiscal year 2017: -$490.87 million | Fiscal year 2016: -$410.11 million | Fiscal year 2015: -$290.07 million | Fiscal year 2014: -$360.40 million | Fiscal year 2013: -$89.23 million | Fiscal year 2012: -$106.01 million | Fiscal year 2011: -$57.65 million | Fiscal year 2010: -$43.52 million | Fiscal year 2009: -$47.59 million | Fiscal year 2008: -$26.25 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: